Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00769223 · ClinicalTrials.gov registry record
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
A clinical trial of Prostate Cancer and Radiation Toxicity, sponsored by University of California, San Francisco.
- Active
- Registry status
- 3,561
- Enrollment target
- 1
- Study location
NCT00769223 is a study of Prostate Cancer and Radiation Toxicity that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 3,561 participants, above the 603-participant average among 735 other Prostate Cancer trials with a reported enrollment target (491% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00769223, a study of Prostate Cancer and Radiation Toxicity, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- 3,561 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients respond to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying the Gleason score, PSA level, and cancer stage in predicting outcome in patients who have undergone radiation therapy for localized prostate cancer.
Conditions Studied
Interventions
- OTHER medical chart review
- OTHER questionnaire administration
- PROCEDURE quality-of-life assessment
- RADIATION radiation therapy
- RADIATION brachytherapy
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,561 participants |
| Start Date | 1993-02-25 |
| Est. Completion | 2026-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00769223
The ClinicalTrials.gov registry entry for NCT00769223 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 3,561 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 603-participant average among 735 other Prostate Cancer trials with a reported enrollment target (491% higher). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which medical chart review is the first listed.
NCT00769223 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00769223 about?
NCT00769223 is a clinical study titled "Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer". RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients respond to treatment and help plan the best treatment. PURPOSE: This clinica...
What is the current status of trial NCT00769223?
This trial is currently active not recruiting. The enrollment target is 3,561 participants. The study started on 1993-02-25. Estimated completion is 2026-01-31.
What conditions does trial NCT00769223 study?
This clinical trial studies the following conditions: Prostate Cancer, Radiation Toxicity.
What interventions are being tested in trial NCT00769223?
The interventions under investigation include: medical chart review (OTHER), questionnaire administration (OTHER), quality-of-life assessment (PROCEDURE), radiation therapy (RADIATION), brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT00769223?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00769223 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.